Status:
COMPLETED
Omega-3-fatty Acids on Age-related Macular
Lead Sponsor:
Mid Atlantic Retina
Collaborating Sponsors:
LifeGuard
Conditions:
Aged Macular Degeneration
Eligibility:
All Genders
20-49 years
Phase:
NA
Brief Summary
Aim: To demonstrate the short-term multi focal electroretinogram (mfERG) effect of oral omega-3-fatty acids in the triglyceride form on dry age-related macular degeneration (AMD). Null hypothesis: Om...
Detailed Description
There is a growing amount of basic science data supporting the use of omega 3 fatty acids in AMD. Koto et al. report that eicosapentaenoic acid, a major omega-3 polyunsaturated fatty acid, prevents CN...
Eligibility Criteria
Inclusion
- i. \>49 year old women and men for the dry AMD arms. \>20 year old for the normal retina arm.
- 1\. No specific race/ethnic background requirements
Exclusion
- i. For dry AMD groups, all patients will be included, regardless of prior or concomitant treatment, and regardless of stage of disease.
- ii. Patients already taking omega-3-fatty acids will be excluded. iii. Women of childbearing age with positive urine pregnancy tests or with plans to conceive during the six month study period will be excluded.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT01258335
Start Date
October 1 2008
End Date
November 1 2010
Last Update
November 22 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mid Atlantic Retina
Philadelphia, Pennsylvania, United States, 19107